Consensus statements	Level	Grade
•Patients who have cirrhosis due to hepatitis C or hepatitis B have the highest rate of developing HCC as compared with chronic hepatitis or cirrhosis due to other etiologies.	II-2
• In non-cirrhotic patients with chronic hepatitis B virus infection: ∘ HBeAg positivity carries higher risk of developing HCC compared with HBeAg negativity. ∘ HBeAg negativity carries higher risk of developing HCC compared with general population.	II-2
• In non-cirrhotic patients with chronic hepatitis C virus infection: ∘ HCC is most often associated with advanced fibrosis however in up to 10% of cases, and it may occur even with mild degrees of fibrosis. ∘ Anti-HCV positivity is associated with higher risk of developing HCC than general population.	II-2
• In patients with HBV- or HCV-related chronic liver disease the risk of HCC is increased if there is concomitant: ∘ HIV co-infection ∘ HBV/HCV co-infection ∘ Chronic alcohol abuse ∘ Obesity ∘ Diabetes mellitus ∘ Aflatoxin exposure	II-2
• In Indian HBV patients, HCC is more often associated with: ∘ HBV genotype D infection/mixed genotype infection ∘ High HBV DNA levels (>10,000 copies/mL) ∘ Persistently elevated serum ALT levels ∘ High level of hepatitis B surface antigen	II-2
• In Indian HCV patients, HCC is more often associated with: ∘ HCV genotype 4 infection ∘ High serum HCV RNA levels	II-2
•Chronic alcohol consumption is an important risk factor for HCC development.	II-2
•Obesity, diabetes mellitus, and non-alcoholic fatty liver disease are important risk factors for HCC development.	II-2
• Regarding HCV patients treated with DAA: ∘ There is no difference in occurrence or recurrence of HCC post-SVR in patients treated with IFN or DAA. ∘ Cirrhosis, low albumin, low platelet, and AFP level posttreatment are indicators of high HCC occurrence even after SVR. ∘ Long-term follow-up studies are required to assess surveillance strategy in patients treated with DAA.	II-2	Strong